Literature DB >> 9488783

Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology.

I A Greer1.   

Abstract

Venous thrombo-embolism remains a major cause of mortality and morbidity following gynaecological surgery and in association with pregnancy and delivery. Specific risk factors can be identified pre-operatively and before or during pregnancy and delivery. Clinicians and units should develop guidelines for risk assessment and the implementation of specific thromboprophylactic measures in patients considered to have significant risk. The main prophylactic techniques are unfractionated and low-molecular-weight heparins and physical methods such as graduated elastic compression stockings. It should be noted that there are particular concerns with regard to the use of pharmacological thromboprophylaxis with both heparin and warfarin in pregnancy. Unfractionated heparin is associated with osteoporotic problems, allergy and heparin-induced thrombocytopenia which can cause significant thrombotic problems. Warfarin is associated with teratogenesis and the risk of bleeding in mother and fetus. Clearly, where antenatal thromboprophylaxis is to be used, the risk of the anticoagulants employed must be weighed against the potential benefits. Such assessment might be best done prior to pregnancy in order that the patient can enter pregnancy with a clear view of the potential hazards and benefits. Low-molecular-weight heparins are being increasingly used in pregnancy but it is unclear to what extent they are safer than unfractionated heparins. However, they do appear to have substantially less risk of heparin-induced thrombocytopenia and possibly less risk of heparin-induced osteoporosis. Increasingly, thrombophilia is recognized as underlying many thrombotic problems, particularly in young women, and when the events occur in association with pregnancy. In view of the complexity in the management of such patients, it is important that they be referred to a unit with specific expertise in the management of thrombophilia.

Entities:  

Mesh:

Year:  1997        PMID: 9488783     DOI: 10.1016/s0950-3552(97)80019-3

Source DB:  PubMed          Journal:  Baillieres Clin Obstet Gynaecol        ISSN: 0950-3552


  11 in total

1.  Venous thromboembolism and pregnancy.

Authors:  Maristella D'Uva; Pierpaolo Di Micco; Ida Strina; Giuseppe De Placido
Journal:  J Blood Med       Date:  2010-03-03

2.  The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C.

Authors:  Cande V Ananth; Carl A Nath; Claire Philipp
Journal:  J Matern Fetal Neonatal Med       Date:  2010-03-24

3.  Previous thrombosis-free pregnancies are no guarantee that subsequent oral contraception may also remain asymptomatic.

Authors:  A Girolami; R Scandellari; L Spiezia; F Tezza
Journal:  J Thromb Thrombolysis       Date:  2007-06-30       Impact factor: 2.300

4.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

Review 5.  Thrombophilia and its treatment in pregnancy.

Authors:  A Eldor
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

6.  Thromboelastography and peripartum coagulation profiles associated with caesarean section delivery.

Authors:  R Smith; T Campbell-Owen; H Maybury; S Pavord; J Waugh
Journal:  Obstet Med       Date:  2009-09-01

Review 7.  Management of preterm infants with intracardiac thrombi: use of thrombolytic agents.

Authors:  P C Rimensberger; J R Humbert; M Beghetti
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

8.  The effect of low molecular weight heparin (dalteparin) on duration and initiation of labour.

Authors:  Nazim Isma; Peter J Svensson; Bengt Lindblad; Pelle G Lindqvist
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

Review 9.  Anticoagulants in pregnancy.

Authors:  Ian A Greer
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

Review 10.  Thrombophilia and pregnancy.

Authors:  Michael J Kupferminc
Journal:  Reprod Biol Endocrinol       Date:  2003-11-14       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.